HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer

Detalles Bibliográficos
Autores principales: Yamaoka, Toshimitsu, Tsurutani, Junji, Sagara, Hironori, Ohmori, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653124/
https://www.ncbi.nlm.nih.gov/pubmed/33209639
http://dx.doi.org/10.21037/tlcr-20-578
_version_ 1783607837337845760
author Yamaoka, Toshimitsu
Tsurutani, Junji
Sagara, Hironori
Ohmori, Tohru
author_facet Yamaoka, Toshimitsu
Tsurutani, Junji
Sagara, Hironori
Ohmori, Tohru
author_sort Yamaoka, Toshimitsu
collection PubMed
description
format Online
Article
Text
id pubmed-7653124
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-76531242020-11-17 HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer Yamaoka, Toshimitsu Tsurutani, Junji Sagara, Hironori Ohmori, Tohru Transl Lung Cancer Res Editorial Commentary AME Publishing Company 2020-10 /pmc/articles/PMC7653124/ /pubmed/33209639 http://dx.doi.org/10.21037/tlcr-20-578 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Yamaoka, Toshimitsu
Tsurutani, Junji
Sagara, Hironori
Ohmori, Tohru
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title_full HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title_fullStr HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title_full_unstemmed HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title_short HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
title_sort her2-d16 oncogenic driver mutation confers osimertinib resistance in egfr mutation-positive non-small cell lung cancer
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653124/
https://www.ncbi.nlm.nih.gov/pubmed/33209639
http://dx.doi.org/10.21037/tlcr-20-578
work_keys_str_mv AT yamaokatoshimitsu her2d16oncogenicdrivermutationconfersosimertinibresistanceinegfrmutationpositivenonsmallcelllungcancer
AT tsurutanijunji her2d16oncogenicdrivermutationconfersosimertinibresistanceinegfrmutationpositivenonsmallcelllungcancer
AT sagarahironori her2d16oncogenicdrivermutationconfersosimertinibresistanceinegfrmutationpositivenonsmallcelllungcancer
AT ohmoritohru her2d16oncogenicdrivermutationconfersosimertinibresistanceinegfrmutationpositivenonsmallcelllungcancer

Ejemplares similares